Schizophrenia Clinical Trial
Official title:
An Open-Label, Long-Term Safety and Tolerability Study of RBP-7000 in the Treatment of Subjects With Schizophrenia
This is a Phase 3, open label study administering RBP-7000 in the treatment of patients with schizophrenia. Study will assess the long-term safety and tolerability of RBP-7000 subcutaneous (SC) injections in subjects with schizophrenia and to continue collecting clinical outcome data with RBP-7000 SC injections in subjects with schizophrenia using the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity Illness (CGI-S) scale.
Patients to be screened must be diagnosed with schizophrenia with a designated score based on
the PANSS, as confirmed by a State, Assessability, Face, Ecological and Rule (SAFER)
interview. "De novo" patients are patients who are already receiving 3- or 4-mg oral
risperidone/day and will not have to complete the "run-in" or "conversion" phases (see below)
and will be assigned to receive RBP-7000 after eligibility has been confirmed. Patients who
completed the double-blind, placebo-controlled, efficacy study of RBP-7000 (RB-US-09-0010,
NCT02109562), conducted in patients with acute schizophrenia (referred to as "roll-over"
patients) will be screened.
All patients will be assigned the 120 mg dose of RBP-7000, which is subject to a one-time
down-titration to 90-mg RBP-7000 for tolerability, at the investigator's discretion. Patients
receiving the 90-mg dose of RBP-7000 who exhibit a worsening in psychiatric symptoms,
confirmed by a total PANSS score >70 or a 20% increase in the PANSS score from the previous
assessment at the 120-mg dose level (before the dose was decreased to 90 mg), can receive a
one-time, up-titration back to 120-mg RBP-7000 at the discretion of the investigator.
"De novo" patients entering into the study are those patients who did not participate in
study RB-US-09-0010 (NCT02109562) and are allocated into three groups with different
pre-study procedures to prepare for the treatment period:
- "Run-in" patients are patients who are not already receiving oral risperidone (as no
other antipsychotic medications are allowed during study participation) and will begin a
14-day run-in period by titrating up to a dose of 3 or 4 mg oral risperidone/day before
the first injection of RBP-7000.
- "Conversion" patients are patients who are receiving oral risperidone doses other than 3
or 4mg/day and will begin a 7-day conversion period to achieve an oral risperidone dose
level of 3 or 4-mg before the first injection of RBP-7000, only if clinically indicated.
- De novo patients taking an oral risperidone dose of 3 or 4 mg/day prestudy will (once
screened/enrolled) receive the first injection of RBP-7000.
"Roll-over" patients entering into the study are patients who completed 56 days of
double-blind treatment in Study RB-US-09-0010. These patients will be eligible to enter the
current study provided that continuation of treatment is clinically warranted, as judged by
the investigator, and that there have been no significant protocol deviations or clinically
relevant adverse events (AEs) that would preclude inclusion in this study. Roll-over patients
will not undergo the complete screening process and will not require either a run-in or
conversion period with oral risperidone. On Day 1 of the open-label study (which is Day 57 of
Study RB-US-09-0010), patients will receive their first injection (120 mg) of open label
RBP-7000.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |